Failing Drug Stock Suffers Another Blow on Drug Trial Data

Core Insights - Novo Nordisk's stock has dropped 7.8% to $43.87, reaching a four-year low of $43.37 after disappointing trial results for its Alzheimer's drug, semaglutide [1] - The stock has seen a significant decline of 58% over the past 12 months, following a peak of $148.15 in June 2024 [2] Trading Activity - Call traders are actively engaging with a 10-day call/put volume ratio of 5.75, indicating heightened interest compared to 98% of the past year's readings [3] - A total of 94,000 calls and 62,000 puts have been exchanged today, which is four times the average intraday pace, with the December 39 put being the most popular [4] - Novo Nordisk's options trading tends to outperform volatility estimates, as indicated by a Schaeffer's Volatility Scorecard (SVS) of 87 out of 100 [4]